Literature DB >> 7213514

Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.

D S Davies, G C Kahn, S Murray, M J Brodie, A R Boobis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7213514      PMCID： PMC1401705          DOI： 10.1111/j.1365-2125.1981.tb01108.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  9 in total

1.  Polymorphism of carbon oxidation of drugs and clinical implications.

Authors:  T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal:  Br Med J       Date:  1978-09-02

2.  Determination of debrisoquin and its 4-hydroxy metabolite in plasma by gas chromatography/mass spectrometry.

Authors:  S L Malcolm; T R Marten
Journal:  Anal Chem       Date:  1976-05       Impact factor: 6.986

3.  Biphasic Michaelis-Menten kinetics for ethoxycoumarin and phenacetin metabolism by human and rat hepatic monooxygenases [proceedings].

Authors:  A R Boobis; M J Brodie; D S Davies; G C Kahn; C Whyte
Journal:  Br J Pharmacol       Date:  1979-07       Impact factor: 8.739

4.  Polymorphic hydroxylation of debrisoquine.

Authors:  G T Tucker; J H Silas; A O Iyun; M S Lennard; A J Smith
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

5.  Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.

Authors:  L Bertilsson; H J Dengler; M Eichelbaum; H U Schulz
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

6.  Toxicological implications of polymorphic drug metabolism.

Authors:  J C Ritchie; T P Sloan; J R Idle; R L Smith
Journal:  Ciba Found Symp       Date:  1980

7.  Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens.

Authors:  A R Boobis; M J Brodie; G C Kahn; D R Fletcher; J H Saunders; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

8.  Deficient metabolism of debrisoquine and sparteine.

Authors:  T Inaba; S V Otton; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1980-04       Impact factor: 6.875

9.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321
  9 in total
  24 in total

1.  Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.

Authors:  M E Veronese; S McLean
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Is the activation of aflatoxin B1 catalysed by the same form of cytochrome P-450 as that 4-hydroxylating debrisoquine in rat and/or man?

Authors:  S Plummer; A R Boobis; D S Davies
Journal:  Arch Toxicol       Date:  1986-02       Impact factor: 5.153

3.  The relationship between the acetylator and the sparteine hydroxylation polymorphisms.

Authors:  D Harmer; D A Evans; L C Eze; M Jolly; E J Whibley
Journal:  J Med Genet       Date:  1986-04       Impact factor: 6.318

4.  Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers.

Authors:  P Dayer; A Kubli; A Kupfer; F Courvoisier; L Balant; J Fabre
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 5.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

Review 6.  Oxidation phenotype and the metabolism and action of beta-blockers.

Authors:  M S Lennard
Journal:  Klin Wochenschr       Date:  1985-04-01

7.  Tolbutamide 4-hydroxylase activity of human liver microsomes: effect of inhibitors.

Authors:  H S Purba; D J Back; M L Orme
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

8.  Interindividual variability in the N-sulphation of desipramine in human liver and platelets.

Authors:  P Romiti; L Giuliani; G M Pacifici
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

9.  The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.

Authors:  D A Evans; D Harmer; D Y Downham; E J Whibley; J R Idle; J Ritchie; R L Smith
Journal:  J Med Genet       Date:  1983-10       Impact factor: 6.318

10.  Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.

Authors:  G C Kahn; A R Boobis; S Murray; M J Brodie; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.